Citations

Clear

92 citation(s) found for "Johnson, Sarah".

Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas
Vasmatzis, George , Johnson, Sarah H. , Knudson, Ryan A., Ketterling, Rhett P. , Braggio, Esteban , Fonseca, Rafaël , Viswanatha, David S., Kip, N. Sertac, Özsan, Nazan , Grebe, Stefan K., Frederick, Lori, Eckloff, Bruce W., Thompson, E. Aubrey , Porcher, Julie C., Asmann, Yan W. , Smith, David I., Kovtun, Irina V. , Ansell, Stephen M. , Feldman, Andrew L. , Law, Mark E. , Kadin, Marshall E. , Milošević, Dragana , Smith, David I., Doǧan, Ahmet , Feldman, Andrew L , Braggio, Esteban , Ketterling, Rhett P , Fonseca, Rafael

Mayo Clinic

Blood | August 2, 2012 | Volume: 120 | Issue: 11 | Pages: 2280-2289

10.1182/blood-2012-03-419937 | PMID 22855598 Get It

Abstract Peripheral T-cell lymphomas (PTCLs) are aggressive malignancies of mature T lymphocytes with 5-year overall survival rates of only ∼ 35%. Improvement in outcomes has been stymied by poor understanding of the genetics and molecular pathogenesis of PTCL, with a resulting paucity of molecular targets for therapy. We developed bioinformatic tools to identify chromosomal rearrangements using genome-wide, next-generation sequencing analysis of mate-pair DNA libraries and applied these tools to 16 PTCL patient tissue samples and 6 PTCL cell lines. Thirteen recurrent abnormalities were identified, of which 5 involved p53-related genes (TP53, TP63, CDKN2A, WWOX, and ANKRD11). Among these abnormalities were novel TP63 rearrangements encoding fusion proteins homologous to ΔNp63, a dominant-negative p63 isoform that inhibits the p53 pathway. TP63 rearrangements were seen in 11 (5.8%) of 190 PTCLs and were associated with inferior overall survival; they also were detected in 2 (1.2%) of 164 diffuse large B-cell lymphomas. As TP53 mutations are rare in PTCL compared with other malignancies, our findings suggest that a constellation of alternate genetic abnormalities may contribute to disruption of p53-associated tumor suppressor function in PTCL.
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing
Feldman, Andrew L. , Smith, David I., Ansell, Stephen M. , Johnson, Sarah H. , Porcher, Julie C., Özsan, Nazan , Wieben, Eric D. , Eckloff, Bruce W., Vasmatzis, George , Doǧan, Ahmet , Smith, David I., Law, Mark E. , Feldman, Andrew L

Mayo Clinic

Blood | October 29, 2010 | Volume: 117 | Issue: 3 | Pages: 915-919

10.1182/blood-2010-08-303305 | PMID 21030553 Get It

Abstract The genetics of peripheral T-cell lymphomas are poorly understood. The most well-characterized abnormalities are translocations involving ALK, occurring in approximately half of anaplastic large cell lymphomas (ALCLs). To gain insight into the genetics of ALCLs lacking ALK translocations, we combined mate-pair DNA library construction, massively parallel (“Next Generation”) sequencing, and a novel bioinformatic algorithm. We identified a balanced translocation disrupting the DUSP22 phosphatase gene on 6p25.3 and adjoining the FRA7H fragile site on 7q32.3 in a systemic ALK-negative ALCL. Using fluorescence in situ hybridization, we demonstrated that the t(6;7)(p25.3;q32.3) was recurrent in ALK-negative ALCLs. Furthermore, t(6;7)(p25.3;q32.3) was associated with down-regulation of DUSP22 and up-regulation of MIR29 microRNAs on 7q32.3. These findings represent the first recurrent translocation reported in ALK-negative ALCL and highlight the utility of massively parallel genomic sequencing to discover novel translocations in lymphoma and other cancers.